RECURRENT CUTANEOUS MELANOMA
Clinical trials for RECURRENT CUTANEOUS MELANOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CUTANEOUS MELANOMA trials appear
Sign up with your email to follow new studies for RECURRENT CUTANEOUS MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a newer immunotherapy drug keep melanoma from coming back?
Disease control OngoingThis phase III trial compares the drug pembrolizumab (MK-3475) to the current standard treatments—high-dose interferon or ipilimumab—in 1,301 patients with high-risk melanoma that has been surgically removed. The goal is to see if pembrolizumab is better at preventing the cancer …
Matched conditions: RECURRENT CUTANEOUS MELANOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 04:00 UTC
-
New combo shows promise in shrinking melanoma before surgery
Disease control OngoingThis study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab can better shrink melanoma tumors before surgery and help prevent them from coming back. About 60 adults with stage III or recurrent melanoma that can be surgically removed will rece…
Matched conditions: RECURRENT CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Can a cancer drug slow down advanced melanoma? small trial hopes to find out
Disease control OngoingThis phase 2 trial is testing the drug ibrutinib in 18 people with stage IV melanoma that has not responded to previous treatments. Ibrutinib works by blocking certain enzymes that help cancer cells grow. The study aims to see if the drug can shrink tumors and how long it keeps t…
Matched conditions: RECURRENT CUTANEOUS MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC